We analyzed several public RNA sequencing datasets and found that melphalan or bortezomib promoted the expression of PD‐L1 in myeloma cells, but did not change the expression of other common immune checkpoints (Figure 2A,B; Figure S2A–C, Supporting Information). This evidence concerns the gene CD274 and plasma cell myeloma.